Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026). Part II: Evaluation and Management of Metastatic...

Area of Science:

• Urology
• Oncology

Background:

• The American Urological Association (AUA) previously published guidelines for advanced prostate cancer.
• New evidence has emerged since the 2023 publication, necessitating an update.

Purpose of the Study:

• To provide an updated clinical framework for the evaluation and management of metastatic castration-resistant prostate cancer (mCRPC).
• To incorporate new evidence into the existing AUA/SUO Advanced Prostate Cancer Guideline.

Main Methods:

• A comprehensive literature review was conducted for studies published between March 16, 2022, and August 26, 2025.
• 38 studies were identified for full-text review as part of the AUA Update Literature Review (ULR) process.
• Relevant studies were integrated into the Guideline's evidence base, leading to updated statements.

Main Results:

• Evidence- and consensus-based statements were developed based on the updated literature review.
• Updated recommendations focus on the evaluation and management of advanced prostate cancer.
• Part II of the amendment specifically addresses treatment of mCRPC.

Conclusions:

• The updated guideline offers new guidance on mCRPC treatment and future directions for advanced prostate cancer management.
• Guidance for non-metastatic castration-resistant prostate cancer (nmCRPC) remains current.
• The guideline will undergo further reviews due to evolving diagnostic and treatment options.